The story behind the Replimune rejection, and San Diego sees a biotech winter

The San Diego biotech market is experiencing a significant downturn, marked by a 'cold snap' that has led to a severe contraction in job opportunities and a dramatic surge in lab space vacancy rates from 1% to over 22%. This indicates a broader industry cost-cutting trend and a challenging operating environment for biotech firms and employment in a key regional hub.

Analysis

The San Diego biotech sector is undergoing a significant contraction, shifting from a period of high growth to a market 'cold snap'. This downturn is quantified by a dramatic increase in lab space vacancy rates, which have surged from a tight 1% to over 22%, indicating widespread cost-cutting and operational scaling-back by resident companies. Consequently, the labor market within this key hub has deteriorated, with job opportunities diminishing. Beyond these macroeconomic pressures, the sector faces stringent regulatory hurdles, as exemplified by the FDA's rejection of Replimune's (REPL) melanoma drug. The specific mention that the FDA's cancer chief was directly involved in the rejection highlights the high bar and potential for significant setbacks in the drug approval process, compounding the risks for companies in the current challenging economic environment.

Key Decisions for Investors

• Investors should be cautious with broad exposure to the biotech sector, particularly small-cap companies and those concentrated in the San Diego hub, given the clear signals of a regional industry downturn and capital constraints.
• The surge in lab space vacancy to 22% presents a material risk for commercial real estate investors and REITs with significant life-science property holdings in the San Diego area.
• The specific and high-level FDA rejection creates a significant headwind for Replimune (REPL); investors should anticipate continued valuation pressure and monitor for company guidance on its revised regulatory strategy for the rejected drug.